Literature DB >> 6141832

Sulphasalazine: a 'new' antirheumatic drug.

T Pullar, H A Capell.   

Abstract

Sulphasalazine was first introduced for the treatment of rheumatoid arthritis in 1942. Following initial enthusiasm, interest waned until 1978 when a large open study suggested that it might have a 'second-line effect'. Since then further studies have confirmed this effect and once again rheumatologists are starting to use sulphasalazine in the treatment of rheumatoid arthritis. In this review we examine the pharmacology of sulphasalazine and its metabolites, comment upon the possible modes of action and review the recent literature pertaining to its use in rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6141832     DOI： 10.1093/rheumatology/23.1.26

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN： 0263-7103


  10 in total

Review 1.  The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis.

Authors:  L E Hart; P Tugwell
Journal:  Postgrad Med J       Date:  1989-12       Impact factor: 2.401

2.  Pharmacological studies of antigen-induced arthritis in BALB/c mice. II. The effects of second-line antirheumatic drugs and cytotoxic agents on the histopathological changes.

Authors:  I M Hunneyball; M J Crossley; M Spowage
Journal:  Agents Actions       Date:  1986-06

3.  Hypogammaglobulinaemia and thrombocytopenia associated with sulphasalazine therapy in rheumatoid arthritis.

Authors:  M Farr; E Tunn; P A Bacon; D H Smith
Journal:  Ann Rheum Dis       Date:  1985-10       Impact factor: 19.103

4.  Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial.

Authors:  C Egsmose; T M Hansen; L S Andersen; J M Beier; L Christensen; L Ejstrup; N D Peters; D M van der Heijde
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

5.  Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid patients treated with sulphasalazine.

Authors:  M Farr; D P Symmons; P A Bacon
Journal:  Ann Rheum Dis       Date:  1985-11       Impact factor: 19.103

6.  Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis.

Authors:  H Mielants; E M Veys; R Joos
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

7.  Which component of sulphasalazine is active in rheumatoid arthritis?

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-25

8.  Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients.

Authors:  M Dougados; P Boumier; B Amor
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

9.  5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?

Authors:  A J Taggart; V C Neumann; J Hill; C Astbury; P Le Gallez; J S Dixon
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Metabolic Profiling of Human Gastric Cancer Cells Treated With Salazosulfapyridine.

Authors:  Kohei Takizawa; Koji Muramatsu; Kouji Maruyama; Kenichi Urakami; Takashi Sugino; Masatoshi Kusuhara; Ken Yamaguchi; Hiroyuki Ono; Yuko Kitagawa
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.